Open AccessTHE DIRECT AND REMOTE RESULTS OF URGENT ANTIHYPERTENSIVE THERAPY AT THE PRE-HOSPITAL STAGE
Author(s) -
В. В. Руксин,
О. В. Гришин
Publication year - 2019
Publication title -
skoraâ medicinskaâ pomoŝʹ
Language(s) - English
Resource type - Journals
ISSN - 2072-6716
DOI - 10.24884/2072-6716-2019-0-3-22-29
Subject(s) - moxonidine , captopril , medicine , furosemide , blood pressure , tolerability , anesthesia , randomized controlled trial , pharmacology , adverse effect , receptor , agonist
A comparison of the efficacy and safety of the ACE inhibitor captopril and the centrally acting moxonidine has been carried out. The randomized trial included 45 patients randomly divided into two groups. 24 patients received captopril, 21 patients received moxonidine. All patients received furosemide. From the very beginning of the study, blood pressure an heart rate was monitored during the day. It was shown that the efficacy and safety of the compared drugs in the first 30 minutes did not differ significantly. However, the effect of captopril, even in combination with furosemide, lasted no more than 6–8 hours, and moxonidine with furosemide — 18–24 hours. Cases of excessive decrease in blood pressure in both groups were rarely observed. Thus, the compared drugs in the first 30 minutes after administration do not differ in effectiveness. At the same time, daily monitoring of blood pressure showed that the effect of captopril more briefly. Moxonidine acts longer and allows you to more effectively control blood pressure fluctuations during the day. High efficacy and good tolerability of both drugs allow recommending them to patients as a means of self-help in case of high blood pressure. The use of daily monitoring of blood pressure allows to make therapy personalized.